Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. - PubMed - NCBI

Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease. - PubMed - NCBI

Cardiovasc Diabetol. 2018 Apr 10;17(1):54. doi: 10.1186/s12933-018-0699-7.

Antidiabetic treatment patterns and specialty care utilization among patients with type 2 diabetes and cardiovascular disease.

Pantalone KM1, Misra-Hebert AD2,3, Hobbs TM4, Ji X3, Kong SX5, Milinovich A3, Weng W5, Bauman J3, Ganguly R5, Burguera B6,7, Kattan MW3, Zimmerman RS6.

Author information

Abstract

BACKGROUND:

To evaluate real-world patient characteristics, medication use, and health care utilization patterns in patients with type 2 diabetes with established cardiovascular disease (CVD).

METHODS:

Cross-sectional analysis of patients with type 2 diabetes seen at Cleveland Clinic from 2005 to 2016, divided into two cohorts: with-CVD and without-CVD. Patient demographics and antidiabetic medications were recorded in December 2016; department encounters included all visits from 1/1/2016 to 12/31/2016. Comorbidity burden was assessed by the diabetes complications severity index (DCSI) score.

RESULTS:

Of 95,569 patients with type 2 diabetes, 40,910 (42.8%) were identified as having established CVD. Patients with CVD vs. those without were older (median age 69.1 vs. 58.2 years), predominantly male (53.8% vs. 42.6%), and more likely to have Medicare insurance (69.4% vs. 35.3%). The with-CVD cohort had a higher proportion of patients with a DCSI score ≥ 3 than the without-CVD cohort (65.0% vs. 10.3%). Utilization rates of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors were low in both with-CVD (4.1 and 2.5%) and without-CVD cohorts (5.4 and 4.1%), respectively. The majority of patient visits (75%) were seen by a primary care provider. During the 1-year observation period, 81.9 and 62.0% of patients with type 2 diabetes and CVD were not seen by endocrinology or cardiology, respectively.

CONCLUSIONS:

These data indicated underutilization of specialists and antidiabetic medications reported to confer CV benefit in patients with type 2 diabetes and CVD. The impact of recently updated guidelines and cardiovascular outcome trial results on management patterns in such patients remains to be seen.

KEYWORDS:

Antidiabetic therapies; Cardiovascular disease; Population health; Type 2 diabetes

PMID:

 

29636104

 

PMCID:

 

PMC5892008

 

DOI:

 

10.1186/s12933-018-0699-7

[Indexed for MEDLINE] 

Free PMC Article